CDNA insider trading
NasdaqGM HealthcareCareDx, Inc. — scored insider trade history from SEC Form 4 filings, parsed and contextualised by FilingIQ.
About CareDx, Inc.
CareDx, Inc. engages in the discovery, development, and commercialization of diagnostic solutions for transplant patients and caregivers in the United States and internationally. It provides AlloSure Kidney, a donor-derived cell-free DNA (dd-cfDNA) solution for kidney transplant patients; AlloMap Heart, a gene expression solution for heart transplant patients; AlloSure Heart, a dd-cfDNA solution for heart transplant patients; and AlloSure Lung, a dd-cfDNA solution for lung transplant patients. The company offers Olerup SSP, which is used to type human leukocyte antigen (HLA) alleles based on sequence specific primer technology; QTYPE that enables precision in HLA typing; and Ottr, a transplant patient management software. In addition, it provides AlloSeq Tx, a high-resolution HLA typing solution; AlloSeq cfDNA, a surveillance solution to measure dd-cfDNA in blood; AlloSeq HCT, a solution for chimerism testing for stem cell transplant recipients; Allocell, a surveillance solution that monitors the level of engraftment and persistence of allogeneic cells for patients who have received cell therapy transplants; and XynQAPI, a transplant quality tracking software, as well as AlloCare, a mobile app that offers a patient-centric resource for transplant recipients. The company offers its products directly to customers, as well as through third-party distributors and sub-distributors. It has a license agreement with Illumina, Inc. for the distribution, development, and commercialization of NGS products and technologies; and Cibiltech SAS to commercialize iBox, a software for the predictive analysis of post-transplantation kidney allograft loss. The company was formerly known as XDx, Inc. and changed its name to CareDx, Inc. in March 2014. The company was incorporated in 1998 and is headquartered in Brisbane, California.
Company website: caredx.com
CDNA insider activity at a glance
FilingIQ has scored 1,207 insider transactions for CDNA since Jan 13, 2015. The most recent filing in our index is dated May 5, 2026.
Across the full history, 126 open-market purchases
and 275 open-market sales
were filed under transaction codes P and S respectively. Compensatory share awards
(code A) and option exercises (code M) are tracked separately and not counted here.
The average FilingIQ composite score on CDNA insider trades is 55.0/100, produced by FilingIQ's multi-factor Form 4 model. Model framework documented at methodology.
Other Healthcare tickers with recent insider activity
Politicians who have traded CDNA
Frequently asked
- How many insider trades does FilingIQ track for CDNA?
- FilingIQ tracks 1,207 Form 4 insider transactions for CDNA (CareDx, Inc.), covering filings from Jan 13, 2015 onwards. 17 of those were filed in the last 90 days.
- Are CDNA insiders net buyers or net sellers?
- Across the full Form 4 history for CDNA, 126 transactions (10%) were open-market purchases and 275 (23%) were open-market sales. Compensatory awards and option exercises are filtered out of these counts.
- Where does CDNA insider data come from?
- Every transaction shown on this page is sourced directly from SEC EDGAR Form 4 filings. FilingIQ parses the raw XML, normalises insider identity across reporting variations, and scores each trade on its multi-factor composite model.
- What sector is CDNA in?
- CareDx, Inc. (CDNA) is classified in the Healthcare sector, specifically Diagnostics & Research, with a current market capitalisation of $1.00B.
Methodology & sources
Every CDNA insider transaction shown on FilingIQ is parsed directly from a public SEC Form 4 XML filing. Insider identity is normalised across reporting variants (CIK changes, name spellings, related-party indirect holdings). The FilingIQ composite score is documented in full on the team page and algo disclosure. Not investment advice; see disclaimer.